Literature DB >> 19222731

Vascular calcification in chronic kidney disease: a clinical review.

Helen Eddington1, Smeeta Sinha, Philip A Kalra.   

Abstract

Vascular calcification, which is associated with arterial stiffness, is now known to be an important predictor of cardiovascular and all-cause mortality in patients with renal disease. This calcification starts developing in the early stages of chronic kidney disease (CKD) and is present in over 50% of patients at the time of dialysis commencement. Once calcification is present it continues to progress, though some medications have been shown to slow this progression. Vascular calcification and bone abnormalities are now both encompassed by the term of CKD-mineral bone disorder and are thought to be part of the same disease process in CKD. Vascular calcification and arterial stiffness have been extensively researched in the renal population and many factors are known to be associated with their presence and progression. This calcification is an important factor to be considered in the management of the renal patient but there are different methods available for its measurement. These details will be discussed further in this review along with evidence available for management of this important complication of renal disease.

Entities:  

Mesh:

Year:  2009        PMID: 19222731     DOI: 10.1111/j.1755-6686.2009.00059.x

Source DB:  PubMed          Journal:  J Ren Care        ISSN: 1755-6678


  6 in total

1.  Recovery of limb perfusion and function after hindlimb ischemia is impaired by arterial calcification.

Authors:  Sara L Zettervall; Xue-Lin Wang; Stephanie Monk; Tonghui Lin; Yujun Cai; Raul J Guzman
Journal:  Physiol Rep       Date:  2021-08

2.  Benefit of Apabetalone on Plasma Proteins in Renal Disease.

Authors:  Sylwia Wasiak; Laura M Tsujikawa; Christopher Halliday; Stephanie C Stotz; Dean Gilham; Ravi Jahagirdar; Kamyar Kalantar-Zadeh; Richard Robson; Michael Sweeney; Jan O Johansson; Norman C Wong; Ewelina Kulikowski
Journal:  Kidney Int Rep       Date:  2017-12-08

3.  Cystatin C Expression is Promoted by VEGFA Blocking, With Inhibitory Effects on Endothelial Cell Angiogenic Functions Including Proliferation, Migration, and Chorioallantoic Membrane Angiogenesis.

Authors:  Zhenkun Li; Shiyuan Wang; Xueyun Huo; Hefen Yu; Jing Lu; Shuangyue Zhang; Xiaohong Li; Qi Cao; Changlong Li; Meng Guo; Jianyi Lv; Xiaoyan Du; Zhenwen Chen
Journal:  J Am Heart Assoc       Date:  2018-11-06       Impact factor: 5.501

4.  Human Heterozygous ENPP1 Deficiency Is Associated With Early Onset Osteoporosis, a Phenotype Recapitulated in a Mouse Model of Enpp1 Deficiency.

Authors:  Ralf Oheim; Kristin Zimmerman; Nathan D Maulding; Julian Stürznickel; Simon von Kroge; Dillon Kavanagh; Paul R Stabach; Uwe Kornak; Steven M Tommasini; Mark C Horowitz; Michael Amling; David Thompson; Thorsten Schinke; Björn Busse; Thomas O Carpenter; Demetrios T Braddock
Journal:  J Bone Miner Res       Date:  2019-12-05       Impact factor: 6.741

5.  Mapping the Serum Proteome of COVID-19 Patients; Guidance for Severity Assessment.

Authors:  Estefanía Nuñez; Irene Orera; Lorena Carmona-Rodríguez; José Ramón Paño; Jesús Vázquez; Fernando J Corrales
Journal:  Biomedicines       Date:  2022-07-13

6.  Blood pressure profile in continuous ambulatory peritoneal dialysis patients.

Authors:  Rizna Abdul Cader; Halim Abdul Gafor; Rozita Mohd; Suriani Ibrahim; W H Wan Haslina; Arba'iyah Bain; Norella Ct Kong
Journal:  EXCLI J       Date:  2012-03-28       Impact factor: 4.068

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.